Abstract
Introduction: Epithelial Ovarian Carcinoma (EOC) comprises the vast majority (almost 90%) of ovarian carcinomas. Chemotherapy is the main treatment in ovarian cancers. The standard of care in the chemotherapeutic is the combination of a platinum (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel). Studies were done to determine whether this combination to be given weekly or every 3 weeks. Patient and Method: Inclusion criteria: 1) Female patients between the ages of 17 - 78 years. 2) Baseline hematological, renal and liver laboratory profiles were within accepted ranges. 3) Performance status of the patients was 0-II. 4) Patients were pathologically proven ovarian cancer. 5) A follow-up period for at least 6 months was required. Exclusion criteria: 1) Patients who had double malignancy were excluded. 2) Performance status more than II. 3) Other comorbidity. Results: We reviewed 69 female patients with EOC, with 60% received every three weeks regimen. Mean age was 53.22 years. At a median follow up of 45.9 months, there was no significant different between the two protocols in terms of mean PFS, 62.35 months (95% CI: 50.08 - 74.63 months) for the three-weekly cohort, and 69.25 months (95% CI: 55.24 - 83.26 months) for weekly protocol (p = 0.613). The three weekly regimen patients had a higher incidence of hospital admission (40% vs 18.5% for the weekly protocol patients), but it didn’t reach a statistical significance (p = 0.063). The three weekly protocol had a significantly higher incidence of causing a neutropenic fever (p = 0.003). Conclusion: In our cohort of Egyptian women with EOC, no significant difference in PFS was found when compared the weekly Carboplatin/paclitaxel when compared to the classic three weeks, although the weekly protocol may be causing less febrile neutropenia and fewer hospital admissions.
Highlights
Epithelial Ovarian Carcinoma (EOC) comprises the vast majority of ovarian carcinomas
At a median follow up of 45.9 months, there was no significant different between the two protocols in terms of mean Progression Free Survival (PFS), 62.35 months for the three-weekly cohort, and 69.25 months for weekly protocol (p = 0.613)
PFS was significantly affected by the first line of treatment received and the extent of the surgical resection as follow: First line of treatment: Data showed that the mean of PFS was 52.6 months for patients who received chemotherapy as 1st line of treatment and 71.6 months for the patients who underwent surgery as 1st line (p = 0.087) (Figure 2)
Summary
Ovarian cancer is classified in various categories, with the Epithelial Ovarian Carcinoma (EOC) comprising the vast majority (almost 90%). Studies were done to determine whether the regimen Carboplatin and paclitaxel given once a week or the standard regimen administered every 3 weeks, would have a better outcome in terms of PFS and the toxicity profile. The NRG-GOG study, by Chan et al, compared the regimen Carboplatin and paclitaxel given once a week compared with the standard regimen administered every 3 weeks regards the side effects, PFS and toxicity profile. We reviewed a cohort of Egyptian women received either protocols and reported on the different PFS and toxicity patterns. We revised the files of patients with EOC presented to NEMROCK in a period starting from January 2011 to December 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
